Devianne-Garrigue I, Pellegrin I, Denisi R, Dupon M, Ragnaud J M, Barbeau P, Breilh D, Leng B, Fleury H J, Pellegrin J L
Laboratoire de Virologie, CHU de Bordeaux, France.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 May 1;18(1):46-50. doi: 10.1097/00042560-199805010-00007.
To evaluate the effect of foscarnet on HIV-1 replication in vivo.
Seventeen AIDS patients with cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV) infection, Kaposi's sarcoma (KS), or a combination of these were treated with foscarnet. HIV RNA quantification (bDNA 2.0, Chiron, Emeryville, CA, U.S.A.), CMV pp65 antigenemia (Argene Biosoft, Varilhes, France), and CMV viremia were determined before and during therapy.
Four patients had CMV retinitis (1 with KS), 2 patients had CMV pneumonia (1 with KS), 1 patient had CMV cholecystitis, 2 patients had VZV infection (1 with KS), 1 patient had HSV-2 infection, and 7 patients had KS alone. The decrease in HIV-1 load was -0.73 +/- 0.39 log copies/ml (p = 2.10(-6)) after 3 days of treatment and -1.15 +/- 0.49 log copies/ml (p < 10(-7)) after 10 days of treatment, compared with day 0. Furthermore, reduction of HIV-1 plasma load during foscarnet therapy did not depend on the presence or absence of CMV disease or on a positive pp65 antigenemia at day 0.
We observed decreased HIV-1 plasma load in all patients treated with foscarnet, regardless of presence or absence of clinical or biologic CMV infection. This decrease supports the proposition that foscarnet anti-HIV-1 activity may be of clinical importance.
评估膦甲酸钠对体内HIV-1复制的影响。
17例患有巨细胞病毒（CMV）、单纯疱疹病毒（HSV）、水痘-带状疱疹病毒（VZV）感染、卡波西肉瘤（KS）或上述情况合并存在的艾滋病患者接受了膦甲酸钠治疗。在治疗前及治疗期间测定HIV RNA定量（分支DNA 2.0，美国加利福尼亚州埃默里维尔的Chiron公司）、CMV pp65抗原血症（法国瓦里勒的Argene Biosoft公司）及CMV病毒血症。
4例患者患有CMV视网膜炎（1例合并KS），2例患者患有CMV肺炎（1例合并KS），1例患者患有CMV胆囊炎，2例患者患有VZV感染（1例合并KS），1例患者患有HSV-2感染，7例患者仅患有KS。与第0天相比，治疗3天后HIV-1载量下降-0.73±0.39 log拷贝/ml（p = 2.10(-6)），治疗10天后下降-1.15±0.49 log拷贝/ml（p < 10(-7)）。此外，膦甲酸钠治疗期间HIV-1血浆载量的降低并不取决于CMV疾病的有无或第0天pp65抗原血症是否为阳性。
我们观察到，所有接受膦甲酸钠治疗的患者，无论有无临床或生物学CMV感染，其HIV-1血浆载量均下降。这一下降支持了膦甲酸钠抗HIV-1活性可能具有临床重要性这一观点。
